Smile Invest Acquires Majority Stake in BAP Medical to Boost Growth

Smile Invest has taken a majority ownership position in BAP Medical as of June 25, 2026, marking a strategic step to expand its footprint in the medical device sector. The acquisition brings BAP Medical, a Belgium-based specialist in medical skincare, into Smile Invest’s portfolio, supporting the company’s ambitions for international growth and product innovation.

BAP Medical, founded in 2006 by Rob Hollweg, develops, manufactures, and distributes medical devices targeting scars, burns, chronic skin conditions, allergies, difficult-to-heal wounds, and ear, nose, and throat (ENT) conditions. Its flagship brands include Alhydran, widely used in burn centers, and BAPSCARCARE and Scarban, recognized for professional scar care. Operating from its ScarPro production facility in Belgium, BAP Medical serves practitioners and patients in over 70 countries through sales offices in the Netherlands, Belgium, the United Kingdom, and a global distribution network.

Rob Hollweg, CEO of BAP Medical, emphasized the cultural fit with Smile Invest, stating, “We are proud and pleased that BAP Medical has found a new partner in Smile Invest that fits perfectly with who we are and what we stand for. Our focus on collaboration, responsibility, and team spirit will continue to drive our growth and innovation.” He added that the partnership will enable BAP Medical to build on its strong foundation and expand both in home markets and internationally.

Representatives from Smile Invest, including Ivo Vincente, Davy Louwers, and Nicolas Costers, highlighted the company’s scientific depth and entrepreneurial culture as key attractions. They noted, “Rob and his team have built a portfolio of strong brands recommended daily by medical specialists across multiple disciplines. The in-house production at ScarPro provides full control over quality and innovation, supported by established markets and a distribution network spanning more than 70 countries. We see significant opportunities to accelerate international growth together.”

The deal’s financial terms were not disclosed. However, the acquisition is expected to generate synergies through cross-selling opportunities, operational efficiencies at the ScarPro facility, and shared research and development resources. Integration plans include aligning sales and distribution networks to enhance market reach and streamlining management while retaining founder involvement.

Industry context shows increasing consolidation in the specialized medical skincare and wound care segments, with competitors likely to respond through heightened M&A activity and investment in innovation. Smile Invest’s acquisition of BAP Medical strengthens its position in the Benelux region and expands its presence in the UK and global markets.

Key challenges include managing cultural integration, maintaining product quality and regulatory compliance during scale-up, and achieving targeted international growth. Both parties express confidence in overcoming these hurdles to realize value creation through accelerated expansion and product portfolio enhancement.

Looking ahead, Smile Invest and BAP Medical plan to leverage their combined expertise to innovate new medical device solutions and enter adjacent markets, reinforcing their commitment to delivering value to medical specialists, practitioners, and patients worldwide.